Past Quarters Earnings Report for Amicus Therapeutics, Inc. (NASDAQ:FOLD)


Amicus Therapeutics, Inc. (NASDAQ:FOLD) moved up 0% and closed its last trading session at $6.08. This Medical Sector stock currently has the Market Capitalization of 855.64 Million. The Average Volume for the stock is measured as 3.57 Million. The Stock has a 52-Week High of $9.83 and 52-Week Low of $4.41 following the dates, it touched its 52-Week High on Apr 1, 2016 and 52-Week Low on Dec 22, 2016. Currently, the Return on Assets value for the trailing twelve months is -20.5% with the Return on Equity and Return on Investment of -55.4% and 0% respectively. This firm currently has YTD (year to date) performance of 22.33 Percent which is awesome. The Short Ratio for the stock is 9.19.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-1.42. The TTM operating margin is 0 percent.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) reports its Earnings on Fri 24 Feb (In 8 Days). The estimated EPS for the current quarter is said to be $-0.3. Following Earnings result, share price were DOWN 14 times out of last 28 Qtrs. The stock has reduced about -1% since it reported its last earnings. The Closing price of Amicus Therapeutics, Inc. (NASDAQ:FOLD) at Last Earnings was $6.14 as compared to the previous closing price of $6.08. The Predicted Move on the 7th day after Amicus Therapeutics, Inc. (NASDAQ:FOLD) will release its earnings at about 10%.

By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Amicus Therapeutics, Inc. (NASDAQ:FOLD) beats earnings by 16%, The Stock Missed Earnings  9  times and has met earnings  1 times.

Earnings History:

We will discuss the past Quarters Earnings below:

Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported its previous quarter on 11/07/2016 where it reported the Actual Earnings of $-0.33. The Closing price before the company posted its earnings was $6.14. The Stock surged on the very next day of earnings and maintained its stock price at $7.43 by showing a % change of 21.01 percent from its previous closing price. The Next Day Volume after Earnings was reported as 4.38 Million. On the 7th day After Earnings Report, the stock hit its share price as $9.2 by showing 49.84% increase from the Stock price Before Earnings were reported.

On 08/09/2016, the stock reported the EPS of $-0.4 where Analysts were projecting the EPS to be $-0.33 showing a difference of $-0.07. Thus Surprise Factor was there with -21.2 percent. Before Earnings Announcement on 08/09/2016, the firm had its stock price of $6.94. And immediately on the next day after earnings announcement, the stock declined -8.65% and closed its trading session at $6.34. On 7th Day after earnings release, Amicus Therapeutics, Inc. (NASDAQ:FOLD) surged to 3.03% from $6.94 to $7.15.

On 05/03/2016, Analysts were suspecting EPS of $-0.34/share where Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported its Actual EPS of $-0.35. Thus showing a Surprise of -2.9 percent. The Closing Price of the stock before earnings was $7.53 while on the Next day the stock closed its trading session at $7.07 with a percentage change of -6.11% from the price of 7.53 before Earnings. The Stock Closing Price on the 7th day of earnings was $6.61.

Company Profile:

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, a small molecule, which has completed Phase III studies that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; ATB200 that is in Phase II studies to treat pompe disease; AT2221, which is in Phase II studies for the treatment of pompe disease; and AT3375 to treat Parkinson’s disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.